
- BioPharm International's BP Elements, March 2022
- Volume 1
- Issue 3
FDA to Hold Public Symposium on Multi-Identification Biomarkers
FDA will hold a symposium discussing the identification of concepts and terminology for multi-component biomarkers from March 23–24, 2022.
FDA’s Center for Drug Evaluation and Research announced a new virtual workshop slated to happen on March 23–24, 2022. The public meeting, “Identification of Concepts and Terminology for Multi-Component Biomarkers,” will be held to discuss high-level terminology surrounding biomarkers.
According to an FDA press release, the goal of the symposium is to develop multi-component biomarker concepts and terminology, identify areas of conceptual language development, and discuss gaps in terminology for concepts and approaches as it relates to multi-component biomarkers.
The symposium will be held via live webcast for the public from 1:00–3:00 pm ET on both days. A full breakdown of the events schedule can be found
Source:
Articles in this issue
over 4 years ago
The Next Step For COVID-19 Vaccinesover 4 years ago
New England Biolabs Releases Lyophilized Master Mixover 4 years ago
Element Biosciences Partners with Genoox on Validation Projectover 4 years ago
European Patent Office Grants Further Patent to Salipro BiotechRelated Content




The BioPharm Brief: FDA Decisions, Vaccine Momentum, and Lymphoma Advances

